Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod


Pfizer Inc's biosimilar of anemia treatments from Amgen Inc and Johnson & Johnson was approved by U.S. health regulators on Tuesday setting it up to compete against the established brands. A company logo is seen at a Pfizer office in Dublin, Ireland November 24, 2015.



from Biotech News